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Abstract 
Objectives: We investigated the factors associated with discrepancies between patients’ and 
caregivers’ ratings about patients’ general QoL and about the domains of Quality of Life in 
Alzheimer’s disease Scale (QoL-AD) at baseline and 12 months. 
Methods: Longitudinal study composed by 114 outpatients with Alzheimer’s disease and 
their caregivers. Patients were assessed with the QoL-AD, Mini Mental State Examination, 
Assessment Scale of Psychosocial Impact of the Diagnosis of Dementia, Cornell Scale for 
Depression, Functional Activities Questionnaire, Neuropsychiatric Inventory and Clinical 
Dementia Rating Scale. Caregivers answered the QoL-AD, Zarit Burden Interview and 
Sociodemographic Questionnaire.  
Results: Linear regression analyses indicated that the factors associated with discrepancies of 
patients’ and caregivers’ ratings of patients’ QoL-AD were impaired awareness and caregiver 
burden at baseline and impaired awareness at 12 months. Also, the factor associated with 
discrepancies in domain memory was impaired awareness and in domain ability to do chores, 
impaired awareness and functional deficit. 
Conclusions: The discrepancies between patients and caregivers were related to awareness 
and caregiver burden at baseline and to awareness at 12 months. These results raise questions 
regarding the subjective nature of QoL and the validity of patients’ evaluation about their own 
QoL. 
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Introduction   
Alzheimer’s disease (AD) presents an insidious onset and progressive deterioration. Memory 
impairment is the main symptom in AD, especially for recent events1. The recognition of 
symptoms by caregivers is associated with early diagnosis, treatment and safety of patients 
affected by dementia2. Patients who lack of awareness, i.e. the capacity to recognize changes 
caused by the deficits related to the disease process3, generally refuse required interventions 
or place themselves at risk while performing activities of daily living (ADL)2. These 
situations may impact quality of life (QoL) and well-being of the patient-caregiver dyad.   
QoL includes four domains: cognitive functioning, ADL, social interaction and well-
being4.  It is also a subjective phenomenon, so the validity of patients’ and caregivers' ratings 
is discussed. The evaluation of QoL should be answered from the perspective of the subject4,5. 
However, in assessments of AD patients’ clinical status, the caregivers’ ratings are often used, 
in particular to measure functionality and neuropsychiatric symptoms. Therefore, one 
controversial aspect is that patients' QoL is frequently measured by caregivers’ ratings4.  
However, studies suggest that patients with mild and moderate AD can reliably evaluate their 
own QoL4,5.  Nevertheless, there are discrepancies between patients and caregivers about AD 
patients’ QoL, and factors have been associated with divergent ratings6,7.  
In longitudinal studies, Missotten et al., 20078 show that the functional and cognitive 
impairments are related to a negative evaluation of QoL by the patient. In contrast, another 
study indicated that depression and anxiety9 - but not cognitive decline – may be associated 
with patients’ negative assessment of their own QoL. When the relationship between 
awareness and QoL was evaluated, Conde-Sala et al., 20146 and Hurt et al., 201010, observed 
that patients with impaired awareness overestimate their own QoL. In contrast, the factors that 
negatively impact caregivers’ ratings seem to be the impairment in functionality and presence 
of neuropsychiatric symptoms5,6,11. Few studies indicate that the caregiver's ratings about the 
patients’ QoL are negatively influenced by caregiver burden6,12 and impaired patients' 
awareness6,13. Therefore, it is observed that the influence of clinical factors on longitudinal 
evaluation of patients and caregivers require further clarification. 
It is also essential to understand, longitudinally, the increase of discrepancies between 
patients’ and caregivers’ ratings about patients’ general QoL and about domains of patients’ 
QoL to observe the maintenance or not of variables (clinical aspects and / or 
sociodemographic data). Nevertheless, longitudinal studies about the increase of discrepancies 
between patients’ and caregivers’ ratings about patients’ QoL are rare. Two studies evaluated 
and found that there were discrepancies in total score and in domains of QoL-AD scale6,7.  
In our previous cross-sectional study14, we found discrepancies between patients’ and 
caregivers’ ratings about patients’ QoL in total score and in domains of QoL-AD scale –
ability to do chores, memory and energy. This study aims to investigate the factors associated 
with the discrepancies between patients’ and caregivers’ ratings about patients’ QoL in total 
and domains of the QoL-AD scale at baseline and 12 months. 
 
Methods 
Design. The study had a longitudinal design. 
Participants 
The data came from a consecutive sample of 114 outpatients seen at Center for Alzheimer’s 
Disease of the Federal University of Rio de Janeiro (UFRJ). They were all diagnosed as 
possible or probable AD according to the criteria of the Diagnostic and Statistical Manual of 
Mental Disorders1. Only individuals with mild AD according to the Clinical Dementia Rating 
(CDR) (CDR = 1)15,16 and Mini-Mental State Examination17,18 scores of 13–26 were included 
in the study. Patients were excluded if they presented aphasia, head trauma, alcohol abuse, or 
epilepsy, and uncontrolled medical problems, such as hypertension and diabetes.  All the 
caregivers were relatives, who routinely cared patients ADL, continuously supervising patient 
situation. 
 
Measures 
The sociodemographic characteristics of the patient and caregiver (age, gender, marital status, 
schooling and family relationship) were recorded.  
 
Patient measurements  
Quality of life. The Quality of Life in Alzheimer’s disease (QoL-AD) scale is a 13-item 
measure of QoL that is completed by both the patients and the caregivers. This questionnaire 
was developed specifically for the assessment of QoL in patient with AD. The QoL-AD 
includes 13 domains: physical health, energy, mood, living situation, memory, family, 
marriage, friends, self, ability to do chores, ability to do things for fun, money and life as a 
whole. The 13 domains are rated as poor (1), fair (2), good (3), or excellent (4), and the total 
score ranges from 13 to 5219,20. Cronbach’s alpha for both patients’ and caregivers’ ratings 
were high range (0.88 and 0.87, respectively)19. 
Cognitive status. The MMSE includes tests of orientation, registration, short-term 
memory, language use, comprehension, and basic motor skills. The total score ranges from 0 
to 3017,18. 
Dementia severity: The CDR measures the severity of dementia. The stages range 
from 0 (no dementia) to 3 (severe dementia) according to the degree of cognitive, behavioral, 
and ADL impairment15,16. 
Awareness: The Assessment Scale of Psychosocial Impact of the Diagnosis of 
Dementia (ASPIDD) is a 30-question scale based on patients’ and caregivers’ ratings. This 
scale was designed to evaluate awareness in patient through the scoring of discrepant 
responses between patients and their caregivers across domains that include awareness of 
cognitive functioning and health condition, ADL, emotional state and social functioning and 
relationships. The ratings of awareness are preserved (0 to 4) to absent (18 or more)3. 
Depressive symptoms: The Cornell Scale for Depression in Dementia (CSDD) assesses 
mood symptoms, physical symptoms, circadian functions, and behavioral symptoms related to 
depression. Scores above seven indicate the presence of depression21,22. 
Functionality: The Pfeffer Functional Activities Questionnaire (PFAQ) is a caregiver-
reported inventory that evaluates the ADL. The ratings for each item ranges from normal (0) 
to dependent (3), with a total of 30 points23,24. 
Neuropsychiatric symptoms: The Neuropsychiatric Inventory (NPI) evaluates 12 
domains: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, 
disinhibition, irritability/lability, apathy, aberrant motor activity, night-time behavior 
disturbances, and appetite and eating abnormalities. Each item is rated in relation to their 
frequency [one (absent) to four (frequently) and intensity one (mild) to three (severe)]. The 
total score can range from zero to 144 points25,26. Cronbach's alpha for overall reliability was 
0.8825. 
 
Caregiver measurements 
Burden: The Zarit Burden Interview (ZBI) consists of 22 items. The caregivers assess 
the impact of the illness on their own lives by indicating how often the experience a particular 
feeling: never (0) to nearly always (4). The total score ranges from zero to 8827,28. 
 
Procedure  
The interviews and questionnaires were administered to patients and caregivers separately and 
independently at baseline and 12 months (2012-2016). The patients had their quality of life, 
cognition and awareness assessed. The caregivers provided information about the patients 
(including sociodemographic, QoL, ADL, neuropsychiatric symptoms, depressive symptoms 
and dementia severity) and had caregiver burden assessed. The caregivers were blinded to the 
statements of the patients. 
The psychiatrists from the Dementia Unit identified eligible people according to the 
inclusion criteria. All of the caregivers had previously been informed of the diagnosis by the 
psychiatrists. Informed consent was obtained for patients and caregivers. The study was 
approved by Ethics Committee of the Institute of Psychiatry at the UFRJ. 
 
Data analysis 
All variables were inspected for normality before analysis. Mann-Whitney U for continuous 
variables and Pearson χ2 test for categorical variables were performed as an initial 
comparison of caregivers and patients’ sociodemographic and clinical characteristics at 
baseline, 12 months and lost cases.  
The Wilcoxon test was used to assess the discrepancies between patients’ and 
caregivers’ ratings of patients’ QoL and to identify the discrepancies between ratings in total 
and various domains of the QoL-AD scale (physical health, energy, mood, living situation, 
memory, family, marriage, friends, self, ability to do chores, ability to do things for fun, 
money and life as a whole) at baseline and 12 months. We used Cohen’s d to measure effect 
size in relation to discrepancies between patients’ and caregivers’ QoL-AD scores. The values 
indicated weak (< 0.5), moderate (0.5-0.8), or high (> 0.8) effects. 
Multivariate linear regression analyses were completed to identify the variables that 
were associated with the discrepancies between patients’ and caregivers’ ratings in total and 
various domains of the QoL-AD scale at baseline and 12 months. We used the total scores of 
the discrepancies at baseline and 12 months such as dependent variables. Also, we used the 
domains of QoL-AD scale that presented discrepancies with high effect size at 12 months 
such as dependent variables. The independent variables were the scores of MMSE, CDR, 
CSDD, PFAQ, ASPIDD, NPI, ZBI and sociodemographic data. Linear regressions were 
conducted using the Enter method. All variables were introduced in a single step, adjusting 
the model with significant variables. In the linear regressions analyses, the coefficients of 
contribution for each variable were calculated by: beta coefficient × the coefficient of 
correlation with the dependent variable. 
The statistical analysis was performed using the Statistical Package for Social 
Sciences (IBM Corporation, Armonk, NY) for Windows v. 22.0, with a significance level that 
was equal to or less than 0.05 and confidence intervals (CI) at 95%. 
 
Results 
Clinical and sociodemographic data of the lost cases 
A total of 39 of the 114 baseline cases were lost during the follow-up, because of refusal of 
the caregiver to be interviewed 21 (53.9%), medical complications 10 (25.7%), mobility 
difficulties 4 (10.3%), patients’ death 3 (7.6%) and patient's refusal to participate in the 
interview 1 (2.5%). The characteristics related to loss of patients were less schooling and 
greater dementia severity. For caregivers, the related factors were high schooling and family 
relationship. The differences between the follow-up and lost cases are shown in Table 1. 
 
Table 1 
Discrepancies of patients’ and caregivers’ ratings of patients’ QoL-AD 
Scores and significant discrepancies of patients’ and caregivers’ ratings of patients’ general 
QoL-AD and of each domain of QoL-AD at baseline and 12 months are provided in table 2.  
At baseline. The highest discrepancies between patients’ and caregivers’ ratings of 
patients’ QoL-AD domains were ability to do chores (d = 0.92); and memory (d = 0.80).  
At 12 months. The highest discrepancies between patients’ and caregivers’ ratings of 
patients’ QoL-AD domains were memory (d = 1.07); and ability to do chores (d = 0.90).  
Table 2 
 
Multivariate linear regression analyses 
At baseline. Linear regression indicated that the factors associated with discrepancies of 
patients’ and caregivers’ ratings of patients’ QoL-AD were impaired awareness (p = 0.001) 
and caregiver burden (p = 0.029). The highest contribution effect was impaired awareness 
(14.6%).  
 At 12 months. Impaired awareness (p < 0.001) was related to discrepancies of patients’ 
and caregivers’ ratings of patients’ QoL-AD. The contribution effect was impaired awareness 
(24.5%).  
 Sociodemographic data, CSDD and PFAQ were not statistically significant at baseline 
and 12 months. 
The linear regression analyses are shown in Table 3. 
Table 3 
 
When the effect of patients’ total QoL-AD score was analysed as an independent 
variable, it explained 15.1% of discrepancy between patients and caregivers at baseline (r2 = 
0.151, β = 0.38, t = 3.60, p = 0.001) and 30.4% of discrepancy at 12 months (r2 = 0.304, β = 
0.55, t = 5.64, p <0.001). 
  Memory domain: Linear regression indicated that the factor associated with 
discrepancies of patients’ and caregivers’ ratings of patients’ QoL-AD in domain memory 
was impaired awareness (p = 0.002).  
Ability to do chores domain: Impaired awareness (p = 0.003), and functional deficit (p 
= 0.022) were related to discrepancies of patients and caregivers’ ratings of patients’ QoL-AD 
in the domain ability to do chores.  
The linear regression analyses are shown in Table 4. 
 
Table 4 
 
Discussion  
In this study, there were discrepancies between patients’ and the caregivers’ ratings of 
patients’ QoL at baseline and also at follow-up, one year after the first evaluation. This result 
is corroborated by other studies that demonstrate the presence of discrepancies in patients’ 
and caregivers’ ratings6,7. At baseline, the factors associated with the discrepancy between 
patients and caregivers were impaired awareness and burden. At 12 months, the discrepancy 
between patients and caregivers was related to impaired awareness. 
 
Effect of caregiver burden on patients QoL assessment 
For caregivers, burden is determined by multiple factors: aspects that are related to patients 
such as level of functional impairment, neuropsychiatric symptoms and clinical 
comorbidities; physical, emotional and social characteristics of caregiver; caregiver coping 
capacity, ability to manage daily patients care, social and health resources29. The cross-
sectional finding about the influence of burden in discrepancy between patients and 
caregivers, is consistent with recent findings that demonstrate an association between 
caregiver's psychosocial well-being (particularly level of burden and depression) and these 
discrepancies in ratings of patients’ QoL6,30. In a study of factors that influence caregiver 
evaluations about patient aspects, caregiver burden was the most important factor to explain 
the variability in assessments, especially in relation to early-stage patients due to greater 
initial impact of the diagnosis of disease29. Caregiver burden can lead to negative assessments 
of patients’ status, particularly in neuropsychiatric symptoms and QoL6,30. Caregivers with 
moderate levels of burden experience difficulties in managing patients care and in their daily 
situations, which negatively affects their ratings about the patients’ QoL4,31.  Thus, burden is a 
multidimensional response to impact caused by the disease. Understanding the elements of 
patients’ disease and the care experience associated with caregiver burden can be useful in 
predicting a positive or negative evaluation of caregivers about patients’ QoL, assisting in 
daily management with patients. 
 
Effect of awareness on patients QoL assessment 
Another factor that influenced the level of discrepancy was impaired awareness at both 
baseline and 12 months6,32. The impairment of awareness has been related to more positive 
patients’ ratings about their own QoL and to more negative assessment by caregivers7,14. This 
lack of awareness suggests that patients' ratings may correspond to mental image before their 
disease6. 
Moreover, patients may be only partially aware of some deficits and changes in some 
domains, but not in others10. The individual variability in awareness and its relation to 
different dimensions may be observed in patients with mild to moderate AD, in studies 
focusing mainly the recognition of cognitive deficits2. Different domains of awareness have 
been studied, such as the ability to monitor their own performance, evaluate the functioning of 
a particular domain and reflect on the nature and impact of diagnostic3,33. Clare et al., 20122 
suggest that two domains of awareness - memory and functionality – show weak correlation 
with the patients’ ratings about their own QoL. Another study indicated significant 
relationship between patients’ ratings of their own QoL and the level of awareness in three 
areas of social-emotional functioning (emotional recognition and empathy, social relations 
and prosocial behavior)33. These aspects illustrate the complexity and heterogeneity of the 
phenomenon. Future studies may investigate the relationship between patterns of change in 
QoL and the perception of specific domains of awareness. 
 
Evaluation of QoL in follow-up 
At 12 months, despite the disease progression, the patients’ ratings about their own QoL did 
not change, while the caregivers’ ratings were slightly worse, even if not statistically 
significant. Studies indicate that patients scores do not change substantially at follow-up8, 
while caregivers scores significantly decrease11. Thus, the stability of patients’ ratings about 
their own QoL over time is in agreement with several studies that did not find a relation 
between patients’ ratings and cognitive decline5,13. Patients may develop mechanisms to cope 
with new difficulties that they are facing, and may not perceive any decline in their QoL7. 
Another explanation might be that the study of Andrieu et al. (2016)7 did not evaluate the 
level of impaired awareness. Thus, it may be assumed that, although the discrepancy is not 
related to cognitive deficit, the participants demonstrate higher lack of awareness and 
presence of neuropsychiatric symptoms, which may have contributed to stability of patients’ 
assessment. This context leads some authors to question the reliability of patients’ ratings 
about their own QoL when they present greater impairment of awareness. The impairment of 
ability to judge and evaluate, may interfere in patients’ perception of their difficulties and lead 
to underestimation of their importance32. Other authors argue that the two perspectives 
(patients and caregivers) may be considered as equally valid and may highlight different 
aspects related to QoL4,5. 
 
Evaluation of QoL domains in follow-up 
In evaluation of QoL, we can also analyze multidimensional perception of patients and 
caregivers, because QoL-AD scale measures aspects regarding cognitive functioning, ADL, 
social interaction and well-being in its 13 domains4. Multidimensional perception is useful to 
explain the importance of various domains of QoL, which can approach aspects of clinical 
practice4. At both moments, patients and caregivers’ evaluation in each domain was compared 
to verify if there was discrepancy. At baseline, we found discrepancies in domains energy, 
mood, memory, friends, ability to do chores and ability to do things for fun. At follow-up, 
domains with significant difference were energy, mood, memory, family, friends, ability to do 
chores, ability to do things for fun and life as a whole. As expected, more domains showed 
discrepancy at follow-up. This finding may be related to differences between what is relevant 
for the assessment of patients and caregivers regarding QoL. Thus, interpretation may be 
ambiguous when patients and caregivers are asked to answer the same questions about QoL34. 
Furthermore, we analyzed which variables were related to domains memory and ability to do 
chores that presented discrepancies with high effect size at 12 months. In domain memory, 
impaired awareness was associated with discrepancies of patients’ and caregivers’ ratings of 
patients’ QoL-AD, while in domain ability to do chores, impaired awareness and functional 
deficit were related to discrepancies. It should be emphasized that most patients presented 
impaired awareness at baseline and this impairment was increased at follow-up; maybe 
patients with memory deficits and decline in other cognitive abilities care less about these 
abilities14. For caregivers, they may perceive the loss of patients' abilities, especially 
functional deficits4,6, and understand them as a source of suffering for themselves and 
patients34. Therefore, patients’ and caregivers’ perception are related to individual aspects and 
should be both considered in evaluation of QoL. 
Some limitations of this study must be acknowledged. One limitation is the loss of 
patients to follow-up of assessment, patients who may have had significant variations in QoL 
may not have been reevaluated. Also, the findings are specific to patients with mild AD and 
may not be generalizable to other stages of AD. Furthermore, the cognitive status was 
evaluated only with MMSE. Finally, clinical aspects of caregivers such as the level of 
depression, and anxiety were not evaluated.  
 
Conclusions  
We identified that discrepancies between patients and caregivers were related to awareness 
and caregiver burden at baseline and awareness at 12 months. Therefore, the concept of QoL 
in AD and the discrepancies between patients and caregivers bring questions regarding the 
subjective nature of construct and the validity of patients’ evaluation about their own QoL. 
The relevance of assessing the discrepancy is the possibility to assist the validity of 
patients’ ratings about their own QoL and understanding dimensional aspects of QoL. 
Furthermore, monitoring of QoL changes in patients with AD may suggest new areas of 
intervention to maintain or improve QoL of patients and caregivers. Moreover, future studies 
should identify strategies to improve accuracy and reliability of QoL and other subjective 
status of patients with AD in order to preserve decision-making and autonomy. 
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 TABLE 1. Comparison (at baseline) of two groups 
         Baseline Lost to follow-up Differences 
  n = 75 n = 39 Test       P 
Patients 
Age, mean (SD) 76.5 (6.9) 77.0  (6.8) 0.2 0.827 a     
Women, n (%) 52 (69.3) 23 (59.0) 1.2 0.269 b  
Schooling, n (%)      15.4 0.002 b 
 1 - 4 years 19 (25.3) 21 (53.8) 
 5 - 8 years 27 (36.0) 14 (35.9) 
 9 - 11 years                     22 (29.3)  1 (2.6) 
 ≥ 12 years   7 (9.3)  3 (7.7) 
Marital Status, n (%)     1.7 0.422 b  
 Married 34 (45.3) 22 (56.4) 
 Widowed 33 (44.0) 15 (38.5) 
 Other  8 (10.7)  2 (5.1)  
QoL–AD, mean (SD) 33.1 (4.5) 33.3  (4.5) 0.1 0.907 a 
MMSE, mean (SD) 21.2 (3.5) 21.1 (3.2) 0.2 0.782 a 
PFAQ, mean (SD)                   12.8 (8.0) 13.2 (9.1) 0.0 0.988 a 
ASPIDD, mean (SD) 5.8 (4.2) 7.3 (5.3) 1.3 0.189 a 
CSDD, mean (SD) 6.5 (5.3) 7.3 (5.4) 0.7 0.440a 
NPI, mean (SD)                   11.0 (10.1) 12.6 (12.9) 0.1 0.902 a 
CDR, n (%)       
 1 75 (100.0) 39  (100.0) 
 
Caregivers 
Age, mean (SD) 59.6 (13.4) 54.8  (14.7)  1.5   0.117 a 
Women, n (%) 65 (86.7) 30  (76.9)  1.7 0.185 b 
Schooling, n (%)     20.6 < 0.000 b 
 1 - 4 years   5   (6.7)   5  (12.8) 
 5 - 8 years 18  (24.0) 24  (61.5) 
 9 - 11 years                     32  (42.7)   5  (12.8) 
 ≥ 12 years 20  (26.7)   5  (12.8) 
 
Family Relationship, n (%)     10.4 0.015 b  
 Spouse 27 (36.0) 18 (46.2)  
 Sons    7 (9.3)   4 (10.3) 
 Daughters  24 (32.0) 17 (43.6) 
 Other (sisters or nieces) 17 (22.7) ---- ------- 
 
Living together, n (%)       0.0 0.785 b  
 Yes 52 (69.3) 28 (71.8) 
  No  23 (30.7) 11 (28.2) 
 
QoL–AD, mean (SD) 29.8 (5.7) 29.5 (5.5)  0.4 0.632 a 
ZBI, mean (SD) 28.3 (15.4) 28.6 (17.2)  0.0    0.929 a 
 
a Mann-Whitney U test; b Pearson χ2 test 
QoL–AD, Quality of Life – Alzheimer’s disease scale; MMSE, Mini Mental State Examination; PFAQ, Functional Activities 
Questionnaire; ASPIDD, Assessment Scale of Psychosocial Impact of the Diagnosis of Dementia; CSDD, Cornell Scale for 
Depression in Dementia; NPI, Neuropsychiatric Inventory; CDR, Clinical Rating Dementia; ZBI, Zarit Burden Interview 
Table 2. Baseline and follow-up scores of clinical variables 
  Baseline  Follow-up  Differences 
  n = 75 n = 75 Test       p d/V 
Patients 
QoL–AD, mean (SD) 33.1 (4.5) 33.1  (5.3) 0.0  0.945 a 0.01 
MMSE, mean (SD) 21.2 (3.5) 19.5 (4.3) 3.7 <0.001 a 0.43 
PFAQ, mean (SD)                   12.8 (8.0) 16.4 (8.5) 5.0 <0.001 a 0.43 
ASPIDD, mean (SD) 5.8 (4.2) 7.5 (4.9) 3.0  0.002 a 0.38 
CSDD, mean (SD) 6.5 (5.3) 6.8 (4.3) 0.4  0.632 a 0.05 
NPI, mean (SD)                   11.0 (10.1) 13.9 (10.4) 2.1  0.028 a 0.28 
CDR, n (%)     34.4 <0.001 b 0.47 
 1 75 (100.0) 47  (62.7) 
 2  …………… 28 (37.3) 
 
Caregivers 
QoL–AD, mean (SD) 29.8 (5.7) 28.8 (5.3)  1.6 0.093 a 0.18 
ZBI, mean (SD) 28.3 (15.4) 29.3 (17.6)  0.4    0.665 a 0.06 
 
a Wilcoxon test; b Pearson χ2 test; Effect size: Cohens d / Cramer’s V 
QoL–AD, Quality of Life – Alzheimer’s disease scale; MMSE, Mini Mental State Examination; PFAQ, 
Functional Activities Questionnaire; ASPIDD, Assessment Scale of Psychosocial Impact of the Diagnosis of 
Dementia; CSDD, Cornell Scale for Depression in Dementia; NPI, Neuropsychiatric Inventory; CDR, Clinical 
Rating Dementia; ZBI, Zarit Burden Interview 
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Table 3. Discrepancies of patients’ and caregivers’ ratings of patients’ QoL-AD  
  Baseline 12 months  
  Patients Caregivers  Discrepancies  Patients    Caregivers  Discrepancies  
  n = 75 n = 75 n =75 n = 75 n = 75 n = 75 
QoL-AD Mean (SD) Mean (SD) Mean (SD) Test  p d Mean (SD)  Mean (SD)  Mean (SD) Test     p d 
Physical health  2.57 (0.66) 2.58 (0.75)  0.01 (0.83) 0.12  0.905 0.01 2.54 (0.87) 2.49 (0.68) -0.05 (0.98) 0.49 0.619 0.06 
    
Energy  2.57 (0.79) 2.14 (0.86) -0.42 (0.93) 3.67 <0.001 0.52 2.58 (0.80) 2.13 (0.81) -0.45 (0.85) 3.98 <0.001 0.55 
 
Mood  2.60 (0.75) 2.36 (0.78) -0.24 (0.89) 2.23  0.025 0.31 2.62 (0.83) 2.40 (0.78) -0.22 (0.87) 2.18 0.029 0.27 
   
Living situation  3.18 (0.56) 3.05 (0.73) -0.13 (0.74) 1.55  0.119 0.19 3.24 (0.69) 3.04 (0.90) -0.20 (1.05) 1.48 0.139 0.24 
 
Memory  2.09 (0.64) 1.58 (0.63) -0.50 (0.97) 3.93 <0.001 0.80 2.09 (0.71) 1.41 (0.54) -0.68 (0.98) 4.86 <0.001 1.07 
 
Family  2.98 (0.62) 2.84 (0.71) -0.14 (0.72) 1.71  0.087 0.21 3.17 (0.68) 2.82 (0.82) -0.34 (0.92) 3.13 0.002 0.46 
 
Marriage  1.48 (1.63) 1.42 (1.56) -0.05 (1.01) 0.79  0.425 0.03 1.57 (1.62) 1.46 (1.55) -0.10 (1.18) 0.79 0.428 0.06 
 
Friends  2.85 (0.71) 2.44 (0.90) -0.41 (0.93) 3.44  0.001 0.50 2.84 (0.78) 2.45 (0.96) -0.38 (0.91) 3.38 0.001 0.44 
 
Self 2.66 (0.72) 2.53 (0.74) -0.13 (1.05) 1.08  0.278 0.17 2.70 (0.76) 2.33 (0.64) -0.37 (0.88) 3.44 0.001 0.52 
 
Ability to do chores  2.73 (0.62) 2.08 (0.78) -0.65 (0.83) 5.27 <0.001 0.92 2.61 (0.73) 1.93 (0.77) -0.68 (0.96) 4.92 <0.001 0.90 
 
Ability to do things for fun  2.44 (0.91) 2.08 (0.92) -0.36 (1.04) 2.87  0.004 0.39 2.37 (0.85) 2.00 (0.83) -0.37 (0.96) 3.09 0.002 0.44 
 
Money  2.16 (0.77) 2.22 (0.78)  0.06 (0.93) 0.63  0.523 0.07 2.17 (0.81) 2.06 (0.89) -0.10 (1.04) 0.94 0.366 0.12 
 
Life as a whole  2.74 (0.69) 2.53 (0.70) -0.21 (0.82) 2.14  0.032 0.30 2.65 (0.70) 2.36 (0.74) -0.29 (0.83) 2.89 0.004 0.40 
 
Total score 33.10 (4.51) 29.89 (5.76) -3.21 (5.74) 4.48 <0.001 0.62 33.17 (5.39) 28.89 (5.33) -4.28 (5.84) 5.23 <0.001 0.79 
 
Wilcoxon test; d, Cohen’s d; QoL–AD, Quality of Life – Alzheimer’s disease scale
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Table 4.  Factors associated with discrepancies between patients and caregivers in QoL-AD  
 
A. Baseline 
r2 = 0.231 β        t p  r CC (%)  
Awareness (ASPIDD) 0.331 3.11 0.003 0.389 12.9  
Burden (ZBI) 0.248 2.28 0.025 0.335 8.3  
Behaviour (NPI) 0.102 0.96 0.341 0.185 1.9 
 F (df), p 7.1 (3, 71)  <0.001  
 Collinearity. TOL / VIF: 0.92-0.95 / 1.04-1.08. Condition Index:  5.3   
B. Follow-up 
r2 = 0.317 β        t p r CC (%)  
Awareness (ASPIDD) 0.465 4.62 <0.001 0.516 24.0  
Burden (ZBI) 0.087 0.83 0.408 0.216 1.9  
Behaviour (NPI) 0.188 1.78 0.079 0.312 5.8 
 F (df), p 10.9 (3, 71)  <0.001  
 Collinearity. TOL / VIF: 0.86-0.95 / 1.05-1.15. Condition Index: 5.3   
Multiple linear regression. F = ANOVA; r2 = coefficient of determination; β = standardized beta 
coefficient: r = Pearson correlation (zero-order); CC = coefficient of contribution (%), [(β. r) x 
100)].  
TOL = Tolerance; VIF = Variance Inflation Factor 
QoL–AD, Quality of Life – Alzheimer’s disease scale; ASPIDD, Assessment Scale of 
Psychosocial Impact of the Diagnosis of Dementia; ZBI, Zarit Burden Interview; NPI, 
Neuropsychiatric inventory. 
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Table 5.  Factors associated with discrepancies between patients and caregivers in domains 
of QoL-AD at 12 months 
 
A. Memory 
r2 = 0.225 β        t p r CC (%)  
Awareness (ASPIDD) 0.383 3.18  0.002 0.437 16.7  
Functional activities (PFAQ) 0.113 0.95 0.341 0.283  3.2 
Burden (ZBI) 0.129 1.14  0.256 0.169 2.2  
Behaviour (NPI) 0.074 0.65  0.515 0.061 0.4 
 F (df), p 4.8 (4, 70)    0.002  
 Collinearity. TOL / VIF: 0.77-0.88 / 1.12-1.29. Condition index: 6.79   
 
B. Ability to do chores  
r2 = 0.333 β        t p r CC (%)  
Awareness (ASPIDD) 0.346 3.10  0.003 0.489 16.9  
Functional activities (PFAQ) 0.282 2.57 0.012 0.449 12.7 
Burden (ZBI) 0.083 0.80  0.426 0.036 0.3  
Behaviour (NPI) 0.148 1.40  0.166 0.229 3.4 
 F (df), p 8.4 (4, 70)   <0.001  
 Collinearity. TOL / VIF: 0.77-0.88 / 1.12-1.29. Condition index: 6.79    
Multiple linear regression. F = ANOVA; r2 = coefficient of determination; β = standardized beta 
coefficient: r = Pearson correlation (zero-order); CC = coefficient of contribution (%), [(β. r) x 
100)].  
TOL = Tolerance; VIF = Variance Inflation Factor 
QoL–AD, Quality of Life – Alzheimer’s disease scale; ASPIDD, Assessment Scale of 
Psychosocial Impact of the Diagnosis of Dementia; FAQ, Functional Activities Questionnaire; 
ZBI, Zarit Burden Interview; NPI, Neuropsychiatric inventory. 
 
 
 
 
